Copyright © 2026 agilon health. All rights reserved. November 17, 2026 Technology-Enabled Clinical and Quality Programs to Advance Patient Outcomes Driving Performance At Scale: The agilon Framework
2 Disclaimers and Forward-Looking Statements FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION Statements in this presentation that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers’ intent, belief or expectation as identified by the use of words such as “believes,” “expects,” “may,” “will,” “shall,” “should,” “would,” “could,” “seeks,” “aims,” “projects,” “is optimistic,” “intends,” “plans,” “estimates,” “anticipates” or the negative versions of these words or other comparable terms. Examples of forward-looking statements include, among other things: statements regarding our expectations related to our strategic plan and its benefits, our growth trajectory, expected revenue, medical costs, net income, total and average membership, Adjusted EBITDA, medical services expense ratio, geography entry costs and other financial projections and assumptions, including our fourth quarter of fiscal year 2026 and full-year 2026 guidance. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be outside our control. These risks and uncertainties that could cause actual results and outcomes to differ from those reflected in forward-looking statements include, but are not limited to: our history of net losses and the expectation that our expenses will increase in the future; failure to identify and develop successful new geographies, physician partners and payors, or execute upon our growth initiatives; success in executing our operating strategies or achieving results consistent with our historical performance; medical expenses incurred on behalf of our members may exceed revenues we receive; our ability to maintain and secure additional contracts with Medicare Advantage payors on favorable terms, if at all; our ability to grow new physician partner relationships sufficient to recover startup costs; availability of additional capital, on acceptable terms or at all, to support our business in the future; significant reduction in our membership; transition to a Total Care Model may be challenging for physician partners; inaccuracy in estimates of our members’ risk adjustment factors, medical services expense, incurred but not reported claims, and earnings pursuant to payor contracts; public health crises, such as pandemics or epidemics, could adversely affect us; the impact of restrictive clauses or exclusivity provisions in some of our contracts with physician partners; our ability to hire and retain qualified personnel; our ability to realize the full value of our intangible assets; security breaches, cybersecurity attacks, loss of data and other disruptions to our information systems; our ability to protect the confidentiality of our know-how and other proprietary and internally developed information; our reliance on our subsidiaries to perform and fund their operations; our use of algorithms, artificial intelligence and machine learning in our business and challenges with properly managing the development and use of these technologies; our reliance on a limited number of key payors; the limited terms of contracts with and our ability to renew them upon expiration; our ability to navigate the changing healthcare payor market; our reliance on , physician partners and other providers to operate our business; our ability to obtain accurate and complete diagnosis data; our reliance on third-party software, data, infrastructure and bandwidth; consolidation and competition in the healthcare industry; the impact of changes to, and dependence on, federal government healthcare programs; uncertain or adverse economic and macroeconomic conditions, including a downturn or decrease in government expenditures; regulation of the healthcare industry and our and our physician partners’ ability to comply with such laws and regulations; federal and state investigations, audits and enforcement actions; repayment obligations arising out of payor audits; negative publicity regarding the managed healthcare industry generally; our use, disclosure and processing of personally identifiable information, protected health information, and de-identified data; failure to obtain or maintain an insurance license, a certificate of authority or an equivalent authorization; changes in tax laws and regulations, or changes in related judgments or assumptions; our indebtedness and our potential to incur more debt; our dependence on our subsidiaries for cash to fund all of our operations and expenses; provisions in our governing documents; our ability to achieve a return on investment depends on appreciation in the price of our common stock; lawsuits not covered by insurance and securities class action litigation; sustainability issues; our stock price may be volatile; non-compliance with the New York Stock Exchange could result in a delisting of our securities; risks related to management transitions, including the transition of our new Chief Executive Officer, and our ability to effectively manage leadership changes; and risks related to other factors discussed in our filings with the Securities and Exchange Commission (the “SEC”), including the factors discussed under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which can be found at the SEC’s website at www.sec.gov. Additionally, ongoing implementation of performance initiatives, leadership changes, and dynamic market conditions create additional uncertainty regarding our future operating and financial performance. Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made. Copyright © 2026 agilon health. All rights reserved.
Copyright © 2026 agilon health. All rights reserved. Today’s speakers Varun Anand Senior Vice President, Product & Interim Chief Technology Officer Dr. Karthik Rao Chief Medical Officer Heidi Hittner Chief Business Operations Officer Dr. Jon Copeland Family Physician, United Physicians
Agenda 1. Total Care Model and clinical care – Dr. Karthik Rao 2. Focus areas a. Technology foundation – Varun Anand b. Clinical pathways – Dr. Karthik Rao c. Physician engagement – Dr. Jon Copeland d. Quality programs – Heidi Hittner & Dr. Jon Copeland 3. Q&A Copyright © 2026 agilon health. All rights reserved.
Copyright © 2026 agilon health. Confidential internal document containing proprietary information. Do not distribute. Total Care Model and clinical care Dr. Karthik Rao Chief Medical Officer, agilon health
6 Copyright © 2026 agilon health. All rights reserved. 01 | Scale of the Total Care Model ~30 Markets Nationwide1 ~2,200 Primary Care Physicians1 500K+ Medicare Patients1 ~$6B Total Medical Expense Managed1 Deep, embedded relationships with physician partners Scalable capabilities across markets and conditions Improving health outcomes and patient experiences Sustainable growth and shared financial value Scaled VBC partner driving primary care physician success Note1 Metrics as of December 31, 2025. Medicare Patients include both Medicare Advantage and ACO-attributed members on the agilon platform.
7 Copyright © 2026 agilon health. All rights reserved. Four integrated capabilities, one physician-led model agilon health Total Care Model Empowering physicians to help their patients live healthier lives Care model agilon delivers a structured end-to-end approach to managing chronic conditions in the primary care setting. Timely insights and coordination with the local care delivery system help keep patients healthier and support appropriate management of overall costs. Partnership agilon works side-by-side with local primary care physicians to transform their practices to improve care for Medicare patients. Network PCPs from across the Network to actively engage with each other to share best practices and identify ways to get better, faster, together. Enablement capabilities Technology, data and AI combine patient health information from separate systems into a single source, giving physicians a comprehensive view to manage their patients’ overall care. Partnership Network Care Model Enablement Capabilities
8 Copyright © 2026 agilon health. All rights reserved. The problem we solve Note1 American Medical Association, “Medicare Physician Updates Compared to Inflation in Practice Costs (2001–2026),” January 2026, based on Federal Register, Medicare Trustees’ Reports, and CMS data. Cumulative change since 2001; inflation measured by the Medicare Economic Index (MEI). Figures approximate. Note2 U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA), “Health Workforce Projections: All Primary Care Physicians (2023–2038),” accessed October 2026. Shortage calculated as (demand − supply) ÷ demand, in full-time equivalents (FTEs); 2038 projections. Figures approximate. Note3 CMS OMH, Mapping Medicare Disparities Tool, 2023 Medicare FFS data; CMS Chronic Conditions Chartbook, 2012 Edition (2010 data). Expenditure distribution is an agilon estimate based on 2010 cost and 2023 prevalence data. Note4 CDC, Fast Facts: Health and Economic Costs of Chronic Conditions, 2026 (based on RAND, Multiple Chronic Conditions in the United States, 2017). Primary care physicians face mounting strain as multiple chronic conditions also drive most of Medicare spend Estimated medical expenditure3 37% 35% 19% 6% 3% Estimated beneficiary distribution3 17% 22% 30% 17% 14% 0% 10% 20% 30% 40% 50% 2023 2028 2033 2038 P C P S h o rt ag e (% D em an d ) Metro Non-Metro Combined Physicians have seen a ~33% decline in real Medicare reimbursement since 2001.1 -10% 0% 10% 20% 30% 40% 50% 60% 70% 2001 2006 2011 2016 2021 2026C u m u la ti ve C h an ge ( % ) Practice Cost Inflation Medicare Physician Payment 20% national PCP shortage by 2038. Double that, ~40%, in non-metro communities.2 ~$800B Estimated Medicare spend on individuals with 4+ chronic conditions3,4 39% Estimated Medicare beneficiaries with 4+ chronic conditions3 Increasing Strain on Physicians Increasing Spend with Complexity Estimated beneficiary distribution3 30% 22% 17% 17% 14% Estimated medical expenditure3 37% 35% 19% 6% 3% 30% 17% 14% 19% 6% 3% 0 conditions 1 condition 2–3 conditions 4-5 conditions 6+ conditions 22% 17% 35% 37%
9 Copyright © 2026 agilon health. All rights reserved. agilon health clinical model BURDEN OF ILLNESS2 CLINICAL INTERVENTIONS Appropriate and accurate diagnosis ✓ Chronic condition reassessment ✓ New condition assessment ✓ Proactive condition identification Most appropriate treatment Access priority Risk stratification + + 5% 10% 40% 45% Serious Illness Care High Risk Rising Risk Relatively Healthy Physician engagement - Through daily point-of-care interactions, actionable performance reporting, and quarterly active panel management — reinforced through aligned physician engagement focused on care quality Technology platform - Deep data paired with point-of-care actions and operational insights to improve care, quality, and cost Comprehensive high-risk care Clinical pathways Fundamentals of value Palliative and hospice Care team touchpoints House calls and high-risk focused clinics Priority chronic conditions • Heart failure • Dementia • Lung health • Kidney disease • Diabetes Care coordination across care episodes • Transitions of care • Post-acute care Annual wellness visits Quality measure- directed screenings % Seniors in risk stratification category based on avoidable utilization1 Note1 Risk stratification pyramid is a conceptual model commonly used in population health management; percentages do not represent agilon patient data. Note2 The Burden of Illness (BOI) Program is designed to improve the collection of accurate information about patient medical conditions for the purpose of advancing quality care and coordination to achieve better health outcomes and decrease health expenditures. agilon health operates at all times consistent with applicable laws, regulations, and guidance, including with respect to RAF coding.
Copyright © 2026 agilon health. Confidential internal document containing proprietary information. Do not distribute. Focus area: Technology foundation Varun Anand Senior Vice President, Product & Interim Chief Technology Officer, agilon health
11 Copyright © 2026 agilon health. All rights reserved. End-user technology tools INTELLIGENCE Analytics & insights DATA PRODUCTS The agilon data ecosystem Technology drives insights across the network Insights • A 360° view of each member — stitching longitudinal payor and provider data across sources and timescales • Actionable insights embedded in operational and clinical workflows — tailored to drive best next steps across every role in the care continuum • Proximity to the physician enables insights to support action at the point of care Financial Data Pipeline 30-60 DAY CLAIMS LAG Membership ClaimsPremium & Statement Payor Census Operational & Clinical Data ~REAL-TIME EMR Integration HIEs1 Real-Time ADTScheduling & Billing Quality Gap ReportsLabs Referrals Data Security & Compliance CARE DELIVERY ENABLEMENT Point-of-Care Insights Prioritized Scheduling High-Acuity Patient Management Clinical Pathways Workflow Cost of Care Workflows Transitions-of-Care Workflow Central Operations Financial Planning Physicians agilon Operations Partner Operations Partner Performance Analytics Technological Intelligence Generative AI Machine Learning Predictive Models Human-in-the-loop Workflows Human Intelligence Actuarial Experts Finance Experts Clinical Experts Market Experts Operational Experts Note1: HIE stands for Health Information Exchange
12 Copyright © 2026 agilon health. All rights reserved. Connecting data to care: earlier identification and treatment of high-risk patients 200M+ clinical documents on the platform5 700M+ lab results across the full continuum5 ~2M hospitalizations tracked5 150M+ claims ingested since 20165 65+ payor partner connections5 120+ EMR1 instances integrated across major vendors5 Outcomes • Earlier and more advanced screening • Improved treatment and adherence • Reduced avoidable hospitalizations and readmissions • Efficient delivery of information and tracking actions Ingestion Financial data from payor partners combined with practice data and clinical feeds from EMRs1, HIEs2 and real-time ADT3 Aggregation A comprehensive view of each member — bringing together information from payors, providers, and the community Action Insights delivered directly into the PCP's4 EMR at the point of patient care Insights6 Identification of potential undiagnosed conditions for physician review, care gaps, screening eligibility, and protocol gaps Note1 EMR stands for Electronic Medical Records. Note2 HIE stands for Health Information Exchange. Note3 ADT stands for Admission, Discharge, Transfer. Note4 PCP stands for Primary Care Physician. Note5 All metrics reflect totals from inception to September 17, 2026. Note6 The Burden of Illness (BOI) Program is designed to improve the collection of accurate information about patient medical conditions for the purpose of advancing quality care and coordination to achieve better health outcomes and decrease health expenditures. agilon health operates at all times consistent with applicable laws, regulations, and guidance, including with respect to RAF coding.
13 Copyright © 2026 agilon health. All rights reserved. PCP GenAI clinical insight memos at the point of care Surfaces relevant clinical conditions, screening needs, and AI-generated clinical insight memos inside the existing EMR2,4 workflow at the point of care. Why it matters: agilon-tuned memos cite dated clinical evidence for PCP3 assessment and are refined by clinicians. All diagnoses are determined by the treating physician based on independent clinical judgment. PHYSICIAN + OPERATOR Clinical pathways: Screening to adherence Identifies patients eligible for critical screenings and flags them to physicians and operators for scheduling. Why it matters: Once diagnosed, the platform tracks protocol adherence to support improved patient outcomes. OPERATOR Prioritized scheduling Worklists sort patients by clinical need so schedulers can focus on the highest-need patients first. Why it matters: More touchpoints translate into more active care management. CARE TEAM Transitions of care Real-time hospital admission and discharge alerts drive rapid outreach to see discharged patients within 7 days. Why it matters: Timely PCP3 follow-up can help reduce readmissions and avoidable utilization. Insights embedded in the care workflow Note1 All images are illustrative. Patient and provider names, dates of birth, EMR IDs, and other patient details shown in screenshots are fictitious. The GenAI clinical insight memo reflects de-identified patient information. Note2 EMR stands for Electronic Medical Records. Note3 PCP stands for Primary Care Physician. Note4 The Burden of Illness (BOI) Program is designed to improve the collection of accurate information about patient medical conditions for the purpose of advancing quality care and coordination to achieve better health outcomes and decrease health expenditures. agilon health operates at all times consistent with applicable laws, regulations, and guidance, including with respect to RAF coding.
Copyright © 2026 agilon health. Confidential internal document containing proprietary information. Do not distribute. Focus area: Clinical Pathways Dr. Karthik Rao Chief Medical Officer, agilon health
15 Copyright © 2026 agilon health. All rights reserved. One repeatable framework scalable across conditions A structured, end-to-end approach to managing chronic conditions in the primary care setting Identify Identification and stratification of high- risk patients based upon data review Diagnose Appropriate testing is completed to confirm or rule out the condition Treat Evidence-based medical therapy is initiated and optimized by the primary care physician (PCP) with additional support as needed (e.g., pharmacy, virtual dementia clinic, etc.) Follow Up Ongoing monitoring, specialist referral as appropriate, and end- of-life care for late- stage patients. Outcomes Measured by earlier identification of conditions, optimized treatment and improved adherence, reduced avoidable utilization, improved patient satisfaction and related quality scores 1 2 3 4 5 Driving measurably better outcomes while reducing avoidable utilization
16 Copyright © 2026 agilon health. All rights reserved. An integrated framework for action-oriented patient care Identify Diagnose Treat Follow-up Outcomes1 2 3 4 5 • Pathway definition • Identification & risk prioritization • Diagnostic criteria and recommendations • Barrier identification & resolution • Surface guideline- aligned treatment • Barrier identification & resolution • Lab, diagnostic, & visit tracking • Incomplete action work • Clinical outcomes measurement • Process performance tracking across the pathway agilon Clinical Pathway Standards • Schedule patients based on priority at right site of care • See patient and engage with recommendations on point-of-care tools • Order & testing evaluation • Clinical decision-making & treatment integrated into point of care • Pharmacy-supported therapy • Reassess & treatment adjustments • Specialty & palliative referrals • Variation review • Implementation reviews PCP / Care Team Action • AI and evidence-based identification of potential undiagnosed conditions for physician review1 • Prioritization workflow tools for schedulers and care teams • Point-of-care insights tool • Point-of-care decision support intelligence • Medication data · pharmacy support tools • Registry · alerts · care pathways workflow · pharmacy/lab data feeds • Referral management · specialist directory · clinical alerts • Performance dashboards - claims/clinical analytics Embedded Technology Note1 The Burden of Illness (BOI) Program is designed to improve the collection of accurate information about patient medical conditions for the purpose of advancing quality care and coordination to achieve better health outcomes and decrease health expenditures. agilon health operates at all times consistent with applicable laws, regulations, and guidance, including with respect to RAF coding.
17 Copyright © 2026 agilon health. All rights reserved. #1 Cause of potentially preventable hospitalization in Medicare patients1 ~40% Increase in age-adjusted HF mortality rate between 2010 and 20232 $30K+ Avg annual cost per CHF patient6 ~20% 30-day readmission rate (national avg)3 Clinical pathway: congestive heart failure (CHF) agilon CHF pathway: identify → diagnose & treat → follow-up Identify • AI flags high-risk CHF patients • Emergency department utilization pattern review • BNP/NT-proBNP4 trend monitoring Diagnose & treat • Provider-level support for guideline directed medical therapy (GDMT) (e.g., POC5 information, patient lists) • Operational reporting for GDMT to drive performance • Pharmacist support for GDMT management Follow-up • Structured 48-72hr post- discharge follow-up • Monthly care coordinator touchpoints • Specialist co-management with cardiology Note¹ Nyweide DJ, et al. JAMA Intern Med. 2013;173(20):1879-1885. Study population: Medicare fee-for-service beneficiaries aged 65 and older. Note² Gorodeski EZ, et al. J Card Fail. 2026. (HF STATS 2026, Heart Failure Society of America). Note³ Blecker S, et al. J Am Coll Cardiol. 2019;73(9):1004-1012. Note⁴ BNP/NT-proBNP stands for B-type natriuretic peptide/N-terminal pro-B-type natriuretic peptide. Note⁵ POC stands for Point of Care. Note⁶ Heidenreich PA, et al. J Card Fail. 2022;28(3):453-466.
18 Copyright © 2026 agilon health. All rights reserved. Evidence-based clinical actions across the heart failure pathway to meaningfully improve outcomes and quality of life for patients Diagnosis Identifying 40-50% of patients at first admission1,2 Treatment Underutilized GDMT3 which leads to unnecessary utilization Function Stage A B C D IP Admission IP Admissions w/ readmissions and declining function Palliative care Underdiagnosed Stage D patients and delays in appropriate palliative care Function Stage A B C D Treatment Titration of GDMT3 to slow progression and avoid unnecessary utilization IP Admission Palliative care Identify stage D patients earlier in course so they can benefit from palliative care Treatment: Aggressive risk factor modification to delay progression Diagnosis Early disease detection via existing imaging or screening of patients in stage A prior to symptom progression and utilization Heart failure patient journey without agilon pathway4 High-quality heart failure journey with agilon pathway4 Note1 Sandhu, Alexander T et al. “Disparity in the Setting of Incident Heart Failure Diagnosis.” Circulation: Heart Failure vol. 14,8 (2021): e008538. doi:10.1161/CIRCHEARTFAILURE.121.008538. Note2 Tisdale, Rebecca L et al. “Predictors of Incident Heart Failure Diagnosis Setting: Insights From the Veterans Affairs Healthcare System.” JACC: Heart Failure vol. 11,3 (2023): 347–358. doi:10.1016/j.jchf.2022.11.013. Note3 GDMT stands for Guideline-Directed Medical Therapy. Note4 Illustrative; conceptual depiction of patient function over time.
19 Copyright © 2026 agilon health. All rights reserved. From frequent hospitalizations to renewed independence A patient’s journey through enhanced care clinic: HF1 Initial Retired patient with COPD1 and HF2; 14 emergency room visits within six months prior to enrollment to 7 in the six months following enrollment. Diagnosis Conditions suboptimally managed at care program enrollment; loss of family medication support led to nonadherence, worsening disease, and situational depression. Intervention Pharmacist-led medication review and reconciliation with enrollment in medication assistance programs, adherence education, and a home visit Follow-Up Optimization of all four GDMT2 pillars; ongoing follow-up with pharmacist who confirms adherence; ongoing and close collaboration with Cardiology for heart failure care Outcomes • ER visits decreased by 50%. • Depressive symptoms improved as conditions were better controlled • Regained independence and confidence managing own health • Returned to a longtime hobby set aside during period of health decline Note1 HF stands for Heart Failure. Note2 GDMT stands for Guideline-Directed Medical Therapy
20 Copyright © 2026 agilon health. All rights reserved. Heart failure pathway supports proactive diagnosis and optimization of Guideline-Directed Medical Therapy (GDMT) Chronic care Overall ~40% 5% Benchmark agilon Identify earlier % Heart failure patients with reduced ejection fraction on all four GDMT drug classes ~20% ~50% Benchmark agilon Better quality NPS 873 2Reduced diagnosis of heart failure in an acute setting 98% agree they receive comprehensive, high-quality care3 1 % Heart failure diagnosis in acute setting Virtual pharmacy patients on all four GDMT pillars Note¹ Sandhu, Alexander T et al. “Disparity in the Setting of Incident Heart Failure Diagnosis.” Circulation: Heart Failure vol. 14,8 (2021): e008538. doi:10.1161/CIRCHEARTFAILURE.121.008538. Benchmark reflects nearly 1M commercially insured and Medicare Advantage adults with new HF diagnoses, 2003–2019. Note2 Keykhaei, Mohammad et al. “National Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction.” JACC: Heart Failure (2026): 103295. doi:10.1016/j.jchf.2026.103295. Note3 agilon health metrics are calculated as of December 31, 2025. Acute-setting diagnosis rate reflects agilon MA patients with new HF diagnoses. 3 3
21 Copyright © 2026 agilon health. All rights reserved. Clinical pathway: serious illness care (palliative and hospice) ~50% Fewer hospital admissions with community-based palliative care1 52.9% Medicare decedents who used hospice in 20242 74% Non-hospice cancer patients dying in a hospital or facility, vs. 14% with3 71% Americans preferring to die at home, vs. 31% who actually do4 agilon Serious Illness Care Pathway: Identify → Diagnose & Treat → Follow-up Identify • High-risk patient review by a dedicated clinical reviewer to surface potential hospice-eligible patients • Eligibility assessment applied • Patients flagged when appropriate and routed to PCP for review Diagnose & Treat • Designated clinical reviewer identifies patients who may meet eligibility criteria such as: • Terminal prognosis (<6 mos) • Evidence of functional and/or clinical decline • Structured clinical summary and individualized care plan created and reviewed by PCP Follow-Up • PCP initiated goals-of-care conversations • Support timely and appropriate hospice enrollment for eligible patients • Structured support for caregivers and patients with RNs and care teams Note1 Scibetta C, et al. The Costs of Waiting: Implications of the Timing of Palliative Care Consultation among a Cohort of Decedents at a Comprehensive Cancer Center. J Palliat Med. 2016;19(1):69-75. Note2 MedPAC, March 2025 Report to Congress. Note3 Obermeyer Z, et al. Association Between the Medicare Hospice Benefit and Health Care Utilization and Costs for Patients With Poor-Prognosis Cancer. JAMA. 2014;312(18):1888-96. Note4 Kaiser Family Foundation. Views and Experiences with End-of-Life Medical Care in the U.S. KFF, 2017.
22 Copyright © 2026 agilon health. All rights reserved. $105.9B 2025 Medicare costs associated with dementia1 60% Dementia cases in the US undetected2 10% Estimated U.S. prevalence among adults 65+ (2016 data)3 60% Dementia patients who wish diagnosis had come sooner4 agilon Dementia Pathway: Identify → Diagnose & Treat → Follow-up Clinical pathway: dementia Identify • Systematic cognitive screening and evaluation for patients 65+ • AI-enabled flagging through clinical pattern recognition5 • Standardized screening approach based on risk-stratification including both brief and comprehensive tools Diagnose & treat • Multiple options to conduct evaluations for applicable patients • PCP conducts full dementia eval • Trained SME performance eval • Telemedicine Referral Partner conducts two-visit eval • Structured diagnosis report and individualized care plan created and reviewed by PCP Follow-up • Care Ecosystem Model: monthly+ patient/caregiver touchpoints • Medication reconciliation, safety screening, and caregiver well-being checks • Advanced care planning & behavioral management guidance • Specialist co-management and referral to community resources Note1 USC Schaeffer Center for Health Policy & Economics. The Cost of Dementia in 2025. April 23, 2025. Note2 Lang et al. BMJ Open. 2017;7(2):e011146. Note3 Manly JJ, et al. JAMA Neurol. 2022;79(12):1242–1249. doi:10.1001/jamaneurol.2022.3543. Note4 Banerjee S, Rahman-Amin M, Eul-Barker N. Int J Geriatr Psychiatry. 2022;37(6). Note5 The Burden of Illness (BOI) Program is designed to improve the collection of accurate information about patient medical conditions for the purpose of advancing quality care and coordination to achieve better health outcomes and decrease health expenditures. agilon health operates at all times consistent with applicable laws, regulations, and guidance, including with respect to RAF coding.
23 Copyright © 2026 agilon health. All rights reserved. 10% Lower hospital admissions1 For agilon MA patients as compared to Medicare FFS benchmarks2 24% Lower readmission rate (readmit) 1 For agilon MA patients as compared to Medicare FFS benchmarks2 8% Lower emergency room utilization (ED) 1 For agilon MA patients as compared to Medicare FFS benchmarks2 87 Patient satisfaction (NPS) 1 Based upon agilon MA patient surveys Results observed across agilon’s embedded programs, partner relationships, and PCP execution Strong execution, demonstrated results Note1 agilon health, 2025 Impact Report (MY 2025 data). Note2 CMS, Medicare Geographic Variation – by National, State & County (2023/2024 data; Original Medicare FFS, standardized spending). data.cms.gov. Accessed October 2026
24 Copyright © 2026 agilon health. All rights reserved. Future pathway creation balances opportunity and complexity while considering time to impact1 A disciplined roadmap: expanding our care model to additional complex care conditions while enhancing existing pathways to improve patient outcomes O p p o rt u n it y Time TODAY Core pathways NEAR-TERM Launch, scale, enhance LONG-TERM Sustained value 1 Enhance current pathways Optimize existing programs to improve patient experience and outcomes 2 Launch & scale new pathways Building upon existing framework and infrastructure to address additional complex medical conditions • Heart failure • Serious illness care • Transitions of care • High-risk patient management • Oncology • Lung health • Musculoskeletal • Cardiology • Dementia Note1 Illustrative; not to scale. Does not represent a financial projection.
Copyright © 2026 agilon health. Confidential internal document containing proprietary information. Do not distribute. Focus area: Physician Engagement Dr. Jon Copeland Family Physician, United Physicians
26 Copyright © 2026 agilon health. All rights reserved. Manage complexity – serious illness care Change trajectory – prevent further decline, protect quality of life Early intervention – alter trajectory Routine care – preserve health Proactive management: aligning status with clinical focus to understand and act on patient trajectory Developed to enhance physician engagement and patient outcomes alongside integrated clinical pathways for the highest-need patients RELATIVELY HEALTHY RISING RISK HIGH RISK SERIOUS ILLNESS CARE 45% 40% 10% 5% Note1 Risk stratification pyramid is a conceptual model commonly used in population health management; percentages do not represent agilon patient data.
27 Copyright © 2026 agilon health. All rights reserved. Proactive management: how it works Identify PCPs and multidisciplinary care teams convene regularly to review high-needs members inclusive of those categorized as: • Rising risk • Declining • Complex Intervene Individualized 90-day action plans are built for intervention across 6 primary domains: • Emergency department / hospital prevention • Visit frequency • Care management • Medication optimization • Caregiver support • Goals of care / hospice Reassess Patients exit intensive management only when certain criteria are met: • No unplanned hospitalizations • Primary care visits proactively scheduled • Care management enrollment • Advanced care plan • Medication optimized • Specialists reviewed • Quality gaps closed
28 Copyright © 2026 agilon health. All rights reserved. Inside a review: proactive management in practice Adapted example of the review process Each partner optimizes their engagement approach in combination with agilon’s technology and clinical pathways to serve their patients and improve health outcomes Action Plan Initial Discussion Date Date of Most Recent Discussion Health Trajectory PCP Visit Frequency Needs CM Needs Palliative/ Hospice Needs Med Review Needs Condition Review Notes/Action Plans 02/01/2026 08/01/2026 Stable None None No No Utilization related to surgeries; is planning two more surgeries this year. Just had pre-op for planned procedure. No action needed. 02/01/2026 08/01/2026 End-of-life 2 Practice CM Palliative No Yes Artery problems. Says there is a reminder note in the chart to discuss palliative/hospice. A year ago, PCP didn’t think patient would be alive now, but patient still is. Last seen, no upcoming appt. Needs PCP 02/01/2026 08/01/2026 Declining/ Rising Risk 4 Practice CM No No No Last PCP visit when patient was preparing for carpal tunnel surgery. CM did engage with patient after, provided education on diabetes, diet, refused to schedule PCP visit. Hospitalization. 02/01/2026 08/01/2026 Declining/ Rising Risk 4 Practice CM Palliative No No Shouldn’t be living at home, needs to be in a SNF. Often misses PCP appts. Dementia and many psychiatric dx. Last appt was telemed, no upcoming appt. CM initiated additional support services. 02/01/2026 08/01/2026 End-of-life 4 None Hospice No No Has had a lot going on. Hospice appropriate patient, can get involved to bridge the gap. Complex patient. Patient went to hospital recently; Residential following and will restart hospice. 02/01/2026 08/01/2026 Declining/ Rising Risk 4 None Palliative No No Urinary tract malignancy & breast cancer – on chemo. Complex cancer patient followed by oncology specialists. Note1 Example adapted from a partner review process. Patient details have been modified and generalized to protect patient privacy.
Copyright © 2026 agilon health. Confidential internal document containing proprietary information. Do not distribute. Focus area: Quality Programs Heidi Hittner Chief Business Operations Officer, agilon health Dr. Jon Copeland Family Physician, United Physicians
30 Copyright © 2026 agilon health. All rights reserved. Quality. Every patient. Every visit. Every opportunity. Better patient care Through whole-person, coordinated care, our programs enable earlier detection of conditions via preventive care and drive better control of chronic disease across our patient population Easier gap closure for our partners Care reinforced by accurate clinical documentation and validation supports accurate quality reporting, with clear and actionable priorities at the point of care and integrated workflows to reduce administrative burden and help close gaps Stronger Stars for payor partners Efforts drive meaningful Stars improvement by closing care gaps and meeting quality measures, ultimately delivering stronger performance and greater value across our network Value differentiation agilon’s quality performance supports: • Strong quality performance across payor partners • Enhanced quality incentives • Measurably stronger patient outcomes A value driver for patients, physicians and payors at every step in the care continuum
31 Copyright © 2026 agilon health. All rights reserved. The clinical case • Hypertension is one of the most common, modifiable drivers of cardiovascular death in the U.S. — and one of the most under-controlled. • The CDC estimates that patients with high blood pressure are 4x more likely to die from stroke and 3x more likely to die from heart disease.5 • Managing blood pressure to target reduces cardiovascular mortality by 20%3, and lowers risk of cardiovascular events such as heart attack, stroke, and kidney disease by 25%3. Blood pressure control: A major modifiable lever on CVD 121.5M U.S. adults ≥20 have high blood pressure1 20% Drop in cardiovascular mortality with medication treatment for BP3 43.7% of adults with hypertension had it controlled in 2017- 2018 (down from 53.8% in 2013-2014)4 670K+ Annual U.S. deaths with hypertension as a cause2 Note1 American Heart Association Newsroom, April 2021. Note2 Cunningham et al., J Public Health Manag Pract, 2023. Note3 Wei et al., JAMA Netw Open, 2020. Note4 Muntner et al., JAMA, 2020. Note5 CDC, Vital Signs, September 2012. Note6 CVD stands for Cardiovascular Disease.
32 Copyright © 2026 agilon health. All rights reserved. A quality playbook across chronic care, prevention & experience • Diabetes: Hemoglobin A1C control, annual eye exam, kidney disease monitoring, medication adherence • Cardiovascular: statins, medication adherence • Hypertension: blood pressure control, medication adherence • Osteoporosis management after fracture • Care Coordination to see patients quickly after inpatient or emergency visit • Comprehensive medication reconciliation and patient engagement • Help prevent unnecessary admissions with proactive primary care touchpoints • Screenings for Preventative Care: colorectal cancer screening, breast cancer screening • Monitoring and deprescribing when patients take multiple medications that may have harmful side effects Chronic condition management Reducing unnecessary hospital admissions Prevention Patient experience • Proactive patient surveys after each PCP visit to gather feedback • Monthly PCP level insights and feedback from their patients with best practices on how to improve where needed
33 Copyright © 2026 agilon health. All rights reserved. 82 Admissions 69 Admissions Effective condition management linked to lower utilization1 Non-controlled ‘24 & ‘25 Controlled ‘24 & ‘25 High blood pressure control for patients with hypertension HbA1c control for patients with diabetes 8 Readmissions 4 Readmissions 10 Readmissions 7 Readmissions 154 Admissions 96 Admissions Controlled agilon patients had ~38% fewer IP admissions Controlled agilon patients had ~30% fewer readmissions Controlled agilon patients had ~16% fewer IP admissions Controlled agilon patients had ~50% fewer readmissions IP admissions per thousand Readmissions Per Thousand IP admissions per thousand Readmissions Per Thousand Note1 Compares agilon MA patients whose condition was controlled vs. not controlled, as defined by the CMS Star measures for Controlling High Blood Pressure (CBP) and Glycemic Status Assessment for Patients with Diabetes (GSD), among patients with complete data in the Enhanced Data Pipeline for measurement years 2024 and 2025. Observational comparison; cohorts may differ in characteristics other than condition control, and results do not establish causation.
34 Copyright © 2026 agilon health. All rights reserved. Strong quality outcomes across MA and ACO populations Star Gap Closure Rate1 4.2★ average Stars rating, agilon-calculated (MY 2025)1 93% chronic condition assessment rate2,3 83% AWV completion rate2 98% Patients who agree they receive comprehensive, high-quality care2 Key Star measures1 3 5 5 4 5 3 3 3 3 3 Transitions Cardiovascular Hypertension Diabetes Cancer MA average agilon Cancer screening Chronic condition management Readmissions & follow up 84% 85% 85% 88% 72% 75% 76% 79% 70% 75% 80% 85% 90% 2022 2023 2024 2025 % G ap C lo su re R at e agilon MA Avg Note1 agilon MA population, 2025 measurement year quality data. Includes a subset of Stars measures; MA average per CMS data. Note2 agilon MA and ACO populations, 2025 measurement year quality and patient survey data. Note3 The Burden of Illness (BOI) Program is designed to improve the collection of accurate information about patient medical conditions for the purpose of advancing quality care and coordination to achieve better health outcomes and decrease health expenditures. agilon health operates at all times consistent with applicable laws, regulations, and guidance, including with respect to RAF coding.
35 Copyright © 2026 agilon health. All rights reserved. A model built to compound value for patients and partners Sharper insights More data As more physicians engage with agilon’s programs, partners benefit—empowering physicians to deliver higher-quality care, reducing the total cost of care, and improving outcomes for the patients who need it most. Stronger relationships Better clinical outcomes More partners agilon delivers • Elevated patient-centered care through deep, embedded partnerships with physician partners • Demonstrable patient outcomes through clinical excellence and physician engagement • Demonstrated quality improvement through comprehensive care and rigorous focus • Expanding network value through durable and deepening payor and provider relationships
36Copyright © 2026 agilon health. Confidential internal document containing proprietary information. Do not distribute. Questions? Answers.